AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal 2024 outlook: low double-digit revenue and EPS growth.
First Quarter Highlights
Net sales were $3.83 billion, in line with guidance, essentially flat on a reported basis year over year and down 1% organically.
GAAP diluted earnings per share